Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study.

Rodrigo Rigo,Philip Q Ding,Eugene Batuyong,Winson Y Cheung,John Walker,Jose G Monzon,Tina Cheng

The oncologist（2023）

引用 0|浏览8

暂无评分

摘要

Real-world adjuvant systemic therapy aligns with clinical trial practice. Recurrence rates remain high despite treatment, and long-term toxicities, including endocrinopathies and chronic inflammatory conditions, are not uncommon.

查看译文

关键词

stage III melanoma, adjuvant, immunotherapy, BRAF-targeted therapy, nivolumab, pembrolizumab, dabrafenib, trametinib, toxicity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要